Windward Bio Debuts on Nasdaq, Shares Jump 68% at Close
Clinical-stage biotech Windward Bio priced its IPO at $17 and surged to $28.50 on its first trading day on Nasdaq.
Clinical-stage biotech Windward Bio priced its IPO at $17 and surged to $28.50 on its first trading day on Nasdaq.
KeyBanc Capital Markets' annual benchmark shows AI-native software companies outpace peers on growth, but stronger unit economics have yet to materialize.
KeyCorp has issued formal notice to redeem all 20 million depositary shares of its Series E Fixed-to-Floating Rate Preferred Stock.
Bybit expands its points-based ByPick game into crypto, sports, and finance markets for its 80 million global users.
Cineverse posted $26M in Q2 FY2027 revenue, a 110% year-over-year jump, with tech-related streams accounting for more than half of sales.
vVARDIS debuted on the New York Stock Exchange under ticker VVVV, offering a drill-free cavity treatment targeting the world's most common non-communicable disease.
Invesco Mortgage Capital announced a $0.12 per share cash dividend for November 2026, payable December 14 to stockholders of record.
Jamie Selway, head of the SEC's Division of Trading and Markets, weighs in on growing complexities surrounding market data.
Cohen & Steers announced pending changes to its RMP, GRM, and IRP realty indexes, effective at close of business on the stated date.
Chinese fintech firm Yiren Digital received a NYSE notification citing failure to meet minimum stock price requirements.
Fly-E Group released unaudited financial results for Q2 and the first half of fiscal year 2027, covering its EV motorcycle and scooter business.
Perpetua Resources Corp. released unaudited Q3 2026 financials and an update on its mining project development.
Centalion Americas refinanced a $3.5B credit facility with a five-bank arranger group, signaling growth momentum under its rebranded U.S. unit.
Hexis Capital Management will transfer its nicotine-focused NICO ETF from NYSE Arca to the Texas Stock Exchange on November 25, 2026.
Azitra, a clinical-stage biopharmaceutical firm focused on dermatology, released its third-quarter 2026 earnings and operational updates.
One concise briefing, weekly. No spam.
By subscribing you agree to receive periodic communications. Unsubscribe anytime via the link in each message or our Unsubscribe page.